Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 2/20 | 0.56 |
| ▸ | AKR1B1 | P15121 | 4/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | AHR | P35869 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CLK1 | P49759 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | TTR | P02766 | 1/20 | 0.41 |
| ▸ | NQO1 | P15559 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3687096 | 0.85 | AKR1B1 (0.56) | MCL1AKR1B1KCNH2PKMRXFP1 | |
| SCHEMBL788583 | 0.78 | PFKFB3 (0.56) | AKR1B1PKMSMN1; SMN2KDM4EMEN1 | |
| SCHEMBL787906 | 0.77 | PFKFB3 (0.55) | AKR1B1PKMSMN1; SMN2KDM4EMEN1 | |
| SCHEMBL13211795 | 0.76 | AKR1B1 (0.63) | MCL1AKR1B1KCNH2PKMRXFP1 | |
| SCHEMBL13484254 | 0.75 | AKR1B1 (0.65) | MCL1AKR1B1KCNH2PKMRXFP1 | |
| Hydrochloric Acid SCHEMBL28301049 | 0.75 | AKR1B1 (0.50) | AKR1B1KCNH2SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL14409919 | 0.73 | MCL1 (0.59) | MCL1AKR1B1KCNH2AHRALDH1A1 | |
| SCHEMBL11686876 | 0.72 | MCL1 (0.77) | MCL1KCNH2PKMRXFP1SMN1; SMN2 | |
| SCHEMBL4615856 | 0.72 | MCL1 (1.00) | MCL1KCNH2PKMRXFP1SMN1; SMN2 | |
| SCHEMBL14648196 | 0.72 | MCL1 (0.77) | MCL1KCNH2PKMRXFP1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7655641-B2 | Sulfonamide derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2010-02-02 | — | — | US | disclosed |
| EP-1450806-B1 | USE OF SULFONAMIDE DERIVATIVES IN THE TREATMENT OF OBESITY OR FOR THE REDUCTION OF FOOD INTAKE | BIOVITRUM AB PUBL (SE) | 2009-04-29 | — | — | EP | disclosed |
| EP-1597248-B1 | SULFONAMIDE DERIVATIVES AS PPAR MODULATORS | LILLY CO ELI (US) | 2007-12-26 | — | — | EP | disclosed |
| US-20060217433-A1 | Sulfonamide derivatives as ppar modulators | ELI LILLY AND COMPANY (US) | 2006-09-28 | — | — | US | disclosed |
| EP-1597248-A2 | SULFONAMIDE DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-11-23 | — | — | EP | disclosed |
| WO-2004073606-A2 | SULFONAMIDE DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-09-02 | — | — | WO | disclosed |
| EP-1450806-A1 | USE OF SULFONAMIDE DERIVATIVES IN THE TREATMENT OF OBESITY OR FOR THE REDUCTION OF FOOD INTAKE | BIOVITRUM AB (SE) | 2004-09-01 | — | — | EP | disclosed |
| US-20030166663-A1 | Use | BIOVITRUM AB (SE) | 2003-09-04 | — | — | US | disclosed |
| WO-2003039547-A1 | USE OF SULFONAMIDE DERIVATIVES IN THE TREATMENT OF OBESITY OR FOR THE REDUCTION OF FOOD INTAKE | BIOVITRUM AB (SE) | 2003-05-15 | — | — | WO | disclosed |
| EP-1228066-A2 | SULFONAMIDE DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 2002-08-07 | — | — | EP | disclosed |
| WO-2001032646-A2 | SULFONAMIDE DERIVATIVES | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217433-A1 | Sulfonamide derivatives as ppar modulators | PPARD, PPARA, PPARG | MCL1 4406/4885AKR1B1 278/4885KCNH2 3126/4885 |
| US-20030166663-A1 | Use | SULT2A1, SULT1A1, SLC5A1 | MCL1 3897/4885AKR1B1 381/4885KCNH2 3144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.